EVM
STRO icon

Eaton Vance Management’s Sutro Biopharma STRO Stock Holding History

Eaton Vance Management’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-23
Closed -$5K – 3011
2021
Q1 		$5K Buy
+23
New +$5.46K ﹤0.01% 2619

Other funds holding STRO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Eaton Vance Management's STRO Position: Q2 2021 in Review

Eaton Vance Management sold out of Sutro Biopharma (STRO) in Q2 2021, closing a stake of 23 shares — an estimated $5K sold.

Eaton Vance Management first reported a position in STRO in Q1 2021 and held it in 1 quarter. The position peaked at $5K in Q1 2021. 124 funds tracked by Wall St. Rank hold STRO as of Q2 2021.

  • Eaton Vance Management reported no remaining Sutro Biopharma position as of Q2 2021 after selling out during the quarter.
  • Eaton Vance Management sold 23 Sutro Biopharma shares in Q2 2021, an estimated $5K.
  • Eaton Vance Management first reported a position in Sutro Biopharma in Q1 2021 and held it in 1 quarter.
  • Eaton Vance Management's Sutro Biopharma position peaked at $5K in Q1 2021.
  • 124 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2021.

Based on Eaton Vance Management's 13F filing for Q2 2021, filed 16 Aug 2021.